Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 31 31 97 53
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Teillbou
Teillbou Mar. 12 at 3:23 AM
$EVAX why this trend of moving up without any f news. I like and hate biotech for that. Of course there must be something behind the scene .. I was condinuisly dropping for months prior to this week exactly
1 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:36 PM
$EVAX biotech tied to cancer vaccine development where traders often speculate ahead of clinical progress updates.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 10 at 7:05 PM
$EVAX today is a good day
0 · Reply
anachartanalyst
anachartanalyst Mar. 9 at 5:02 PM
$EVAX https://anachart.com/wp-content/uploads/ana_temp/1773075701_soc-img.jpg
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 7 at 10:27 AM
$EVAX Evaxion outlines expanded cash runway into 2H 2027 and anticipates data milestones for EVX-01 and EVX-04 (NASDAQ:EVAX) | Seeking Alpha https://share.google/Jyce2V2ox5MzZdYaG
1 · Reply
Manwiththeplan
Manwiththeplan Mar. 6 at 3:58 PM
$EVAX earnings call: questions to the CEO: what did you do during your first months anwers: nothing
1 · Reply
lestatk
lestatk Mar. 6 at 10:08 AM
$EVAX 🚀🚀🚀🚀
1 · Reply
StockNews_Live
StockNews_Live Mar. 5 at 2:29 PM
$EVAX Evaxion A/S provides business update and announces full year 2025 financial results. Highlights include the historic licensing of their infectious disease vaccine candidate EVX-B3 by MSD, unprecedente…
0 · Reply
Lenni_D
Lenni_D Mar. 5 at 1:08 PM
$EVAX https://evaxion.ai/?press_release_id=10901 This should be an AI only company. All the humans do is fuck up😅
2 · Reply
Manwiththeplan
Manwiththeplan Mar. 5 at 1:01 PM
$EVAX when dissapointing news?
0 · Reply
Latest News on EVAX
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript

Mar 6, 2026, 2:45 PM EST - 9 days ago

Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript

Evaxion announces business update and full year 2025 financial results

Mar 5, 2026, 9:28 AM EST - 10 days ago

Evaxion announces business update and full year 2025 financial results

Evaxion plans to file 2025 annual report later today

Mar 5, 2026, 8:02 AM EST - 10 days ago

Evaxion plans to file 2025 annual report later today

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Mar 2, 2026, 8:00 AM EST - 13 days ago

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Jan 13, 2026, 8:00 AM EST - 2 months ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Jan 7, 2026, 8:00 AM EST - 2 months ago

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Dec 19, 2025, 12:43 PM EST - 3 months ago

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 19, 2025, 7:00 AM EST - 3 months ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Dec 6, 2025, 2:00 PM EST - 3 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 4 months ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 4 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:56 PM EST - 4 months ago

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 4 months ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 4 months ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 4 months ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 4 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 22, 2025, 5:13 PM EDT - 5 months ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 5 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 5 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 5 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 5 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion A/S - Special Call

Sep 25, 2025, 11:07 AM EDT - 6 months ago

Evaxion A/S - Special Call

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 6 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:29 PM EDT - 7 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 7 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 8 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 9 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 10 months ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 10:43 AM EDT - 10 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 10 months ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 26, 2025, 8:47 AM EDT - 10 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 10 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 10 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 11 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Evaxion to present at World Vaccine Congress

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 11:21 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 1 year ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 1 year ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 1 year ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 1 year ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 1 year ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 1 year ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Teillbou
Teillbou Mar. 12 at 3:23 AM
$EVAX why this trend of moving up without any f news. I like and hate biotech for that. Of course there must be something behind the scene .. I was condinuisly dropping for months prior to this week exactly
1 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:36 PM
$EVAX biotech tied to cancer vaccine development where traders often speculate ahead of clinical progress updates.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 10 at 7:05 PM
$EVAX today is a good day
0 · Reply
anachartanalyst
anachartanalyst Mar. 9 at 5:02 PM
$EVAX https://anachart.com/wp-content/uploads/ana_temp/1773075701_soc-img.jpg
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 7 at 10:27 AM
$EVAX Evaxion outlines expanded cash runway into 2H 2027 and anticipates data milestones for EVX-01 and EVX-04 (NASDAQ:EVAX) | Seeking Alpha https://share.google/Jyce2V2ox5MzZdYaG
1 · Reply
Manwiththeplan
Manwiththeplan Mar. 6 at 3:58 PM
$EVAX earnings call: questions to the CEO: what did you do during your first months anwers: nothing
1 · Reply
lestatk
lestatk Mar. 6 at 10:08 AM
$EVAX 🚀🚀🚀🚀
1 · Reply
StockNews_Live
StockNews_Live Mar. 5 at 2:29 PM
$EVAX Evaxion A/S provides business update and announces full year 2025 financial results. Highlights include the historic licensing of their infectious disease vaccine candidate EVX-B3 by MSD, unprecedente…
0 · Reply
Lenni_D
Lenni_D Mar. 5 at 1:08 PM
$EVAX https://evaxion.ai/?press_release_id=10901 This should be an AI only company. All the humans do is fuck up😅
2 · Reply
Manwiththeplan
Manwiththeplan Mar. 5 at 1:01 PM
$EVAX when dissapointing news?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 4:25 PM
$EVAX RSI: 43.10, MACD: -0.2327 Vol: 0.14, MA20: 3.27, MA50: 4.12 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 2 at 2:02 PM
$EVAX https://uk.finance.yahoo.com/news/evaxion-announce-business-full-2025-130000292.html
2 · Reply
It_S_Me
It_S_Me Feb. 28 at 6:51 PM
$EVAX
0 · Reply
lestatk
lestatk Feb. 27 at 4:41 PM
$EVAX
0 · Reply
Olsen71
Olsen71 Feb. 26 at 4:40 PM
$EVAX worst stock I've had in my portfolio to date.. We'll end up going down to around 1.2 again if they don't get some money in the bank soon and sell some products 🤔 No news at all for a long time 😳
3 · Reply
Manwiththeplan
Manwiththeplan Feb. 24 at 5:29 PM
$EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Feb. 20 at 6:17 PM
$EVAX i like the silence
1 · Reply
snipethad
snipethad Feb. 20 at 3:59 PM
$EVAX Evaxion Biotech develops AI-driven vaccines. Clinical validation is required. Early-stage risk dominates valuation.
0 · Reply
Manwiththeplan
Manwiththeplan Feb. 19 at 2:27 PM
$EVAX https://www.streetinsider.com/dr/news.php?id=26026484&gfv=1
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 12:11 AM
$EVAX Current Stock Price: $3.17
0 · Reply
baldaldo
baldaldo Feb. 17 at 3:16 PM
$EVAX Do they even talk with Merck anymore? Or anybody?
0 · Reply
PortfolioArbiter
PortfolioArbiter Feb. 17 at 1:02 PM
$EVAX Pre-revenue biotech; early-stage.
0 · Reply